OakChart

Nyxoah SA

NYXHHealthcare·Medical Devices·Belgium·Micro·NASD·Nov 11 • 3:58 PM ET

0.9000+0.0001 (0.01%)
2026-11-12 06:25 CET
Market cap
91.66 USD m
Revenue, TTM
33.50 USD m
Net income, TTM
-104.86 USD m
Free cash flow, TTM
-86.15 USD m
EPS diluted, TTM
-1.99
P/E
-
Compare

Price

NYXH against its 20, 50 and 200-day averages
2050200beatmiss
1.002.003.004.005.002.3M4.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NYXHclose 0.9020-day 0.9150-day 1.23200-day 2.340.90

84.8% under the 52-week high of 5.92 on 12 Nov 2025. 52-week low 0.80 on 23 Oct 2026. Last 15 sessions, 21.8% high to low

Volume 1.02× normal · the line is the 50-bar volume average

Profile

NYXH
52-week range, 2% of the way up
0.805.92

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

IPOApr 28, 2021
Beta1.78
ATR, 14d0.07
Rel volume1.02
Short float0.41%
Insider own19.83%
Inst own23.81%

Snapshot

6 groups

Valuation

Index-
Market Cap91.66M
Enterprise Value65.29M
Income-104.86M
Sales33.50M
Book/sh0.76
Cash/sh0.86
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOApr 28, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S2.74
P/B1.19
P/C1.05
P/FCF-
EV/EBITDA-
EV/Sales1.95
Quick Ratio2.05
Current Ratio2.17
Debt/Eq0.79
LT Debt/Eq0.53
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.99
EPS next Y-0.74
EPS next Q-0.20
EPS this Y56.09%
EPS next Y38.35%
EPS next 5Y44.19%
EPS past 3/5Y-28.04% -28.17%
Sales past 3/5Y51.67% 170.10%
EPS Y/Y TTM19.90%
Sales Y/Y TTM432.53%
EPS Q/Q72.36%
Sales Q/Q357.81%
EarningsNov 05 AMC
EPS/Sales Surpr.44.01% -6.94%

Ownership

Insider Own19.83%
Insider Trans0.00%
Inst Own23.81%
Inst Trans14.12%
ROA-75.19%
ROE-153.00%
ROIC-89.01%
Gross Margin38.06%
Oper. Margin-287.34%
Profit Margin-313.04%
SMA20-0.73%
SMA50-26.91%
SMA200-61.55%
Trades-

Technical

Shs Outstand101.84M
Shs Float81.64M
Short Float0.41%
Short Ratio1.06
Short Interest0.33M
52W High5.92 -84.80%
52W Low0.80 12.50%
Volatility6.67% 6.21%
ATR (14)0.07
RSI (14)37.78
Beta1.78
Rel Volume1.02
Avg Volume312.23K
Volume318,645

Performance

Perf Week4.72%
Perf Month-29.69%
Perf Quarter-43.04%
Perf Half Y-70.78%
Perf YTD-80.43%
Perf Year-84.07%
Perf 3Y-81.56%
Perf 5Y-96.32%
Perf 10Y-
Recom1.86
Target Price3.30
Prev Close0.90
Price0.90
Change %0.01%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
May 12, 2026DowngradeSStifelBuy → Hold$5+455.6%
Jul 31, 2023InitiatedHH.C. WainwrightBuy
Jul 19, 2023InitiatedRRobert W. BairdNeutral
Apr 21, 2022InitiatedOOppenheimerOutperform$30+3,233.3%
Apr 06, 2022InitiatedWWolfe ResearchPeer Perform$21+2,233.3%
Dec 21, 2021ResumedCCantor FitzgeraldOverweight$47+5,122.2%
Jul 28, 2021InitiatedCCantor FitzgeraldOverweight$43+4,677.8%

Peers

Mkt cap
TickerCompanyMkt cap
INSPInspire Medical Systems Inc1.80B
LIVNLivaNova PLC5.01B
CVRXCVRx Inc19.95M
NPCENeuroPace Inc429.73M
ECORElectroCore Inc71.13M
STIMNeuronetics Inc125.92M
RMDResmed Inc33.55B
BWAYBrainsway Ltd ADR452.41M
INGNInogen Inc149.51M
VVOSVivos Therapeutics Inc3.04M

News

latest 14 of 200
  • Nyxoah Narrows Its Loss And Accelerates U.S. Growth, But The Ramp Is Slower Than Promised And Leading Indicators Are Cooling (Earnings Whispers) -5.63%
  • Nyxoah Reports Third Quarter 2026 Financial and Operating Results (GlobeNewswire)
  • Nyxoah's Guidance Cut Puts Q3 US Launch Momentum And Stale Estimates On Trial (Earnings Whispers)
  • Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire) +6.35%
  • Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 (GlobeNewswire) -14.05%
  • Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026 (GlobeNewswire) -6.72%
  • Nyxoah Appoints Liam Kelly as Chief Executive Officer (GlobeNewswire) +9.66% -13.84%
  • CVRx names John Landry as CFO (MedTech Dive)
  • Nyxoah Announces Chief Financial Officer Transition (GlobeNewswire) -5.41%
  • Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio System (GlobeNewswire)
  • Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients (GlobeNewswire) +16.56%
  • Information on the total number of voting rights and shares (GlobeNewswire)
  • Nyxoah SA (NYXH) (Q2 2026) Earnings Call Highlights: US Revenue Surges 22% Sequentially, $110M ... (GuruFocus.com) -7.09%
  • Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.197-0.352-0.20110.2210.985
2026Q22026-08-05-0.667-0.448-0.6728.858.746
2026Q12026-05-12-0.432-0.587-0.4327.467.146
2025Q42026-03-19-0.677-0.637-0.6826.525.376
2025Q32025-11-13-0.732-0.686-0.7362.292.286
2025Q22025-08-18-0.643-0.659-0.6241.561.546
2025Q12025-05-14-0.671-0.523-0.6291.191.887
2024Q42025-03-13-0.503-0.497-0.4941.372.167
2024Q32024-11-06-0.536-0.498-0.5451.371.477
2024Q22024-08-06-0.468-0.461-0.4600.841.867
2024Q12024-05-14-0.451-0.456-0.4511.331.307
2023Q42024-03-05-0.413-0.387-0.4081.991.897
2023Q32023-11-08-0.285-0.473-0.2891.051.517
2023Q22023-08-08-0.491-0.449-0.4871.221.187
2023Q12023-05-16-0.498-0.367-0.4940.481.325
2022Q42023-03-22-0.560-0.310-0.5241.423.055

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.826-0.906-0.7710.100.60
2021FY-1.275-1.158-1.3720.942.43
2022FY-1.317-1.090-1.2713.364.65
2023FY-1.685-1.668-1.6704.744.61
2024FY-1.964-1.855-1.9574.916.17
2025FY-2.729-2.476-2.72211.5710.22
2026FY--1.199--37.66
2027FY--0.739--73.74
2028FY--0.475--114.98
2029FY-0.100--183.66
2030FY-0.033--274.47

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0650511.6610.8912.48
2026Q4S2026-10-2350214.7010.9016.38
2026Q4S2026-10-2051115.6515.1716.38
2026Q4S2026-10-1652315.6515.1716.38
2026Q4S2026-09-2452315.6815.1716.38
2026Q4S2026-09-2352315.6915.1716.38
2026Q4S2026-09-2152215.7315.1716.38
2026Q4S2026-09-1152315.7315.1716.38
2026Q4S2026-08-1452315.7415.1716.38
2026Q4S2026-08-1151315.3813.9016.38
2026Q4S2026-08-0661415.4313.9016.38
2026Q4S2026-07-2860215.6213.9016.99
2026Q4S2026-07-2761215.6213.9016.99
2026Q4S2026-07-0864215.6213.9016.99

Estimate history

EPS, annual-0.546-0.5-0.442-0.771-1.372-1.271-1.67-1.957-2.668-1.9892
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.545-0.494-0.629-0.624-0.736-0.682-0.432-0.672-0.203
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000.0791.0073.2414.7014.8911.30833.5
Period201720182019202020212022202320242025TTM
Sales, quarterly1.3911.3471.121.5192.3056.5697.4558.92410.55
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual21.42421.42421.42422.09825.77225.84628.67437.42743.026101.84
Period201720182019202020212022202320242025MRQ
Shares, quarterly34.38937.42737.42737.43637.54543.02643.662100.073101.84
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue33.5011.314.894.703.241.010.080.000.00
Cost of Goods Sold Incl. D&A20.759.234.624.343.242.320.740.480.11
Gross Profit12.752.080.270.360.00-1.32-0.66-0.48-0.11
Selling, General and Administrative Excl. Other109.0097.7464.9849.7134.4630.0212.668.0110.44
Research and Development41.1844.7635.7327.3915.605.001.721.641.62
Other Operating Expense0.000.000.000.000.00--0.000.00
Operating Income-96.25-95.66-64.70-49.35-34.45-31.33-13.32-8.49-10.56
Interest Expense8.065.582.081.301.221.921.110.700.60
Unusual Expense0.16-1.730.440.102.860.000.000.000.00
Net Income Before Taxes-102.46-100.53-61.04-48.28-31.59-29.12-13.85-9.38-10.66
Income Taxes2.411.143.03-1.561.233.520.110.080.05
Consolidated Net Income-104.86-101.67-64.08-46.72-32.82-32.65-13.96-9.46-10.71
Net Income From Continuing Operations-104.86-101.67-64.08-46.72-32.82-32.65-13.96-9.46-10.71
Net Income-104.86-101.67-64.08-46.72-32.82-32.65-13.96-9.46-10.71
EPS (Recurring)-1.04-2.70-1.95-1.67-1.19-1.37-0.77-0.44-0.50
EPS (Basic, Before Extraordinaries)-1.99-2.67-1.96-1.67-1.27-1.37-0.77-0.44-0.50
EPS (Diluted)-1.99-2.67-1.96-1.67-1.27-1.37-0.77-0.44-0.50
EBITDA-88.54-90.60-61.76-46.80-32.42-29.37-12.61-8.01-10.44
Non-Operating Income (Expense)2.01-1.026.182.476.954.130.57-0.190.50
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.544.143.222.112.131.132.060.270.02
Price To Sales Ratio4.1816.1757.2728.0043.70499.744,448.00--
Gross Margin38.0618.385.557.640.06-130.63-842.03--
Operating Margin-287.34-845.90-1,323.09-1,049.82-1,062.97-3,111.15-16,931.93--
Net Margin-313.04-899.05-1,310.24-993.84-1,012.48-3,241.67-17,746.43--
Shares Outstanding101.8443.0337.4328.6725.8525.7722.1021.4221.42
Market Capitalization91.6691.66275.09132.99128.97571.95536.89--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue10.558.927.456.572.301.521.121.35
Cost of Goods Sold Incl. D&A5.755.705.214.092.591.431.241.16
Gross Profit4.803.222.252.48-0.290.09-0.120.19
Selling, General and Administrative Excl. Other30.1227.1526.2825.4528.2522.6221.6920.33
Research and Development11.869.398.8111.1313.8910.939.0312.27
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-25.33-23.93-24.03-22.97-28.54-22.53-21.81-20.15
Interest Expense1.850.631.384.200.510.460.631.40
Unusual Expense-6.2313.03-6.750.10-0.66-0.20-0.93-0.10
Net Income Before Taxes-20.16-37.77-18.20-26.33-27.90-23.04-23.43-16.07
Income Taxes0.350.550.461.04-0.340.320.132.22
Consolidated Net Income-20.51-38.33-18.65-27.37-27.56-23.36-23.56-18.29
Net Income From Continuing Operations-20.51-38.33-18.65-27.37-27.56-23.36-23.56-18.29
Net Income-20.51-38.33-18.65-27.37-27.56-23.36-23.56-18.29
EPS (Recurring)-0.25-0.51-0.54-0.68-0.75-0.63-0.65-0.50
EPS (Basic, Before Extraordinaries)-0.20-0.67-0.43-0.68-0.74-0.62-0.63-0.49
EPS (Diluted)-0.20-0.67-0.43-0.68-0.74-0.62-0.63-0.49
EBITDA-23.47-21.82-22.02-21.23-26.86-21.66-21.00-19.34
Non-Operating Income (Expense)0.79-0.190.460.950.49-0.24-1.915.37
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.621.360.770.790.980.751.560.59
Price To Sales Ratio4.183.906.8216.7227.6352.7156.0664.71
Gross Margin45.4936.1230.1637.72-12.535.67-10.9013.78
Operating Margin-240.04-268.10-322.35-349.68-1,238.34-1,483.66-1,947.65-1,495.57
Net Margin-194.44-429.50-250.22-416.60-1,195.74-1,537.84-2,103.76-1,357.80
Shares Outstanding101.84100.0743.6643.0337.5437.4437.4337.43
Market Capitalization91.66168.88127.49197.92172.17279.97240.02275.09

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments56.3788.5963.79101.24154.10112.936.5719.2112.13
Short Term Receivables8.906.376.593.462.862.012.370.840.69
Inventories5.474.883.660.940.390.070.000.000.00
Other Current Assets0.361.711.461.371.930.130.010.000.00
Total Current Assets71.11101.5675.50107.00159.28115.158.9520.0512.83
Net Property, Plant & Equipment6.288.548.816.005.964.891.560.390.44
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable2.021.671.290.180.190.110.090.080.08
Intangible Assets58.8552.1751.4942.6628.8019.406.440.000.00
Deferred Tax Assets0.100.080.060.051.550.040.020.030.03
Other Assets0.780.000.000.000.000.000.000.000.00
Total Assets139.14164.03137.15155.89195.77139.5817.0620.5513.38
Short Term Debt Incl. Current Port. of LT Debt27.921.411.341.181.291.330.810.330.47
Accounts Payable16.129.846.805.324.541.461.550.930.72
Income Tax Payable4.634.472.203.903.19----
Other Current Liabilities8.846.205.525.503.395.042.551.030.90
Total Current Liabilities57.5021.9315.8615.9112.427.834.912.292.10
Long Term Debt21.5022.0412.6911.5011.9812.798.856.325.85
Provision for Risks Charges1.641.040.210.060.100.050.030.000.00
Deferred Tax Liabilities0.000.020.010.001.50----
Other Liabilities0.801.360.000.000.000.000.610.000.00
Total Liabilities81.4446.3928.7727.4726.0120.6714.418.607.95
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity57.70117.64108.38128.43169.76118.922.6511.955.44
Total Shareholders Equity57.70117.64108.38128.43169.76118.922.6511.955.44
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity57.70117.64108.38128.43169.76118.922.6511.955.44
Total Liabilities & Stockholders Equity139.14164.03137.15155.89195.77139.5817.0620.5513.38
Book Value Per Share1.343.143.784.976.595.380.120.560.25
Tangible Book Value Per Share-0.031.751.983.325.474.50-0.180.560.25
Full-Time Employees153.70183.60146.80137.50105.8071.9042.5040.1036.40
Price to Book Ratio1.192.351.150.995.054.74---
Return on Assets-67.07-42.55-31.88-18.66-19.47-17.82-50.32-63.13-
Return on Equity-115.97-56.70-39.46-22.01-22.62-22.68-129.61-123.21-
Return on Invested Capital-128.37-45.87-38.59-23.45-17.96-10.60-82.30-58.63-103.68
Quick Ratio1.144.414.536.6712.8014.691.828.776.11
Current Ratio1.244.634.766.7312.8314.701.828.776.11

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-101.45-100.53-61.04-48.28-31.59-29.12-13.85-9.38-10.66
Depreciation7.645.062.942.552.031.960.710.480.11
Other Funds (Non Cash)9.8413.203.560.83-0.93-1.903.531.150.71
Funds from Operations-83.96-82.26-54.54-44.90-30.49-29.06-9.61-7.75-9.84
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.656.063.20-3.780.09-1.351.621.070.24
Cash from Operating Activities-83.31-76.20-51.34-48.67-30.40-30.41-8.00-6.68-9.60
Capital Expenditures-4.42-4.25-6.57-98.36-125.03-13.97-12.17-6.47-0.09
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses1.310.000.010.000.000.000.000.000.00
Purchase or Sale of Investments-57.3533.80-13.540.000.000.000.000.000.00
Purchase of Investments-91.47-47.46-105.820.000.000.000.000.000.00
Sale Or Maturity of Investments34.1281.2592.280.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00-0.01-0.010.00
Other Sources-0.000.00132.9730.500.000.000.000.00
Cash from Investing Activities-60.4529.55-20.1034.61-94.53-13.97-12.19-6.49-0.09
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock111.7123.5575.4219.820.2791.87118.080.0017.70
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock111.7123.5575.4219.820.2791.87118.080.0017.70
Proceedsfrom Stock Options111.7123.5575.4219.820.2791.87118.080.0017.70
Issuance or Reduction of Debt, Net-21.8410.75-0.52-0.31-0.431.221.200.00
Net Financing Active Other Cash Flow-0.48-0.32-0.560.000.000.000.000.000.00
Other Financing Activities Uses-0.48-0.32-0.560.000.000.000.000.000.00
Cash from Financing Activities148.3943.7984.3018.49-0.8690.85118.760.8217.70
Exchange Rate Effect0.98-1.860.74-0.402.174.60-0.030.09-0.10
Net Change in Cash5.61-4.7213.604.02-123.6251.0798.55-12.267.90
Free Cash Flow-86.15-77.11-52.60-51.38-31.33-32.15-8.64-6.73-9.69
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments87.54111.8029.8856.3726.4150.46
Short Term Receivables11.9511.3810.318.905.406.87
Inventories5.434.245.015.477.146.26
Other Current Assets0.450.760.580.361.561.11
Total Current Assets105.38128.1745.7871.1140.5164.70
Net Property, Plant & Equipment6.836.786.906.287.489.48
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets53.1854.9056.7358.8558.8860.34
Deferred Tax Assets0.010.010.010.100.030.09
Other Assets1.452.160.960.781.020.00
Total Assets168.93192.61112.45139.14109.98136.72
Short Term Debt Incl. Current Port. of LT Debt20.5527.0819.8127.921.161.55
Accounts Payable14.2614.4514.5616.1211.2311.04
Income Tax Payable4.724.605.024.633.974.68
Other Current Liabilities9.147.917.928.848.027.31
Total Current Liabilities48.6754.0447.3157.5024.3824.59
Long Term Debt40.6241.5021.7621.5023.7024.75
Provision for Risks Charges1.601.171.201.641.300.47
Deferred Tax Liabilities0.080.050.040.000.040.04
Other Liabilities0.770.830.820.800.680.71
Total Liabilities91.7497.5971.1281.4450.1050.56
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity77.1995.0241.3357.7059.8886.16
Total Shareholders Equity77.1995.0241.3357.7059.8886.16
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity77.1995.0241.3357.7059.8886.16
Total Liabilities & Stockholders Equity168.93192.61112.45139.14109.98136.72
Book Value Per Share0.760.950.951.341.592.30
Tangible Book Value Per Share0.240.40-0.35-0.030.030.69
Full-Time Employees---153.70--
Price to Book Ratio1.191.792.182.882.002.79
Return on Assets-75.19-67.96-74.78-67.18-68.89-56.80
Return on Equity-153.00-123.53-136.89-116.16-104.97-78.09
Return on Invested Capital-17.41-28.07-29.56-34.55-32.97-21.06
Quick Ratio2.052.290.861.141.372.38
Current Ratio2.172.370.971.241.662.63

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-19.57-37.66-18.20-26.01-29.39-24.84
Depreciation1.812.092.011.731.740.94
Other Funds (Non Cash)-4.6815.37-5.594.752.993.29
Funds from Operations-22.44-20.19-21.78-19.54-24.67-20.61
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.461.02-3.434.53-0.071.58
Cash from Operating Activities-23.90-19.18-25.21-15.01-24.73-19.04
Capital Expenditures-0.48-1.49-1.03-1.42-0.35-1.49
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses1.31-0.530.53-0.000.000.00
Purchase or Sale of Investments-31.85-23.935.85-7.4211.0921.50
Purchase of Investments-31.63-39.010.00-20.84-8.21-13.85
Sale Or Maturity of Investments-0.2215.085.8513.4219.3035.35
Other Uses0.000.000.000.000.000.01
Other Sources0.00--0.000.000.00
Cash from Investing Activities-31.01-25.945.35-8.8410.7420.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.8888.410.0024.180.060.05
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.8888.410.0024.180.060.05
Proceedsfrom Stock Options-0.8888.410.0024.180.060.05
Issuance or Reduction of Debt, Net-0.1716.02-0.0522.520.000.00
Net Financing Active Other Cash Flow-0.11-0.11-0.03-0.24-0.050.09
Other Financing Activities Uses-0.11-0.11-0.03-0.24-0.050.09
Cash from Financing Activities-1.33103.97-0.4346.18-0.34-0.22
Exchange Rate Effect-0.180.780.330.050.06-1.32
Net Change in Cash-56.4359.63-19.9722.38-14.26-0.58
Free Cash Flow-24.39-20.67-26.06-15.03-24.78-19.68

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.41%0.3M81.6M308.43K
2026-10-150.26%0.2M81.6M268.26K
2026-09-300.40%0.3M81.3M295.96K
2026-09-150.33%0.3M81.3M313.26K
2026-08-310.30%0.2M81.3M329.70K
2026-08-140.58%0.5M81.3M323.60K
2026-07-310.55%0.4M79.9M309.95K
2026-07-150.52%0.4M79.9M292.99K
2026-06-300.37%0.3M79.7M255.74K
2026-06-151.03%0.8M79.9M214.07K
2026-05-291.75%0.4M24.2M45.35K
2026-05-151.37%0.3M24.2M49.10K
2026-04-301.35%0.3M24.2M49.45K
2026-04-151.33%0.3M24.2M56.98K
2026-03-311.26%0.3M24.5M55.53K
2026-03-131.09%0.3M24.5M47.32K
2026-02-271.12%0.3M24.1M46.69K
2026-02-130.98%0.2M24.1M45.22K
2026-01-301.20%0.3M24.1M44.70K
2026-01-150.93%0.2M24.1M40.04K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-05SEC
2026-10-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-20SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-29SEC
2026-09-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-22SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-07-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-09SEC
2026-07-01SCHEDULE 13G/ASEC
2026-06-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-23SEC
2026-06-22SCHEDULE 13GSEC
2026-06-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-11SEC
2026-06-11SCHEDULE 13D/ASEC
2026-06-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-08SEC
2026-06-08424B5SEC
2026-06-05FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-06-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-04SEC
2026-06-04424B5SEC
2026-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-12SEC
2026-03-26S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-2620-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-19SEC
2026-01-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-30SEC
2026-01-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-14SEC
2025-12-29SCHEDULE 13GSEC
2025-12-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-19SEC
2025-12-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-05SEC
2025-11-24SCHEDULE 13D/ASEC
2025-11-17424B5SEC
2025-11-176-K/A2025-11-14SEC
2025-11-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
AIGH Capital Management LLC14.37%
BNP Paribas Asset Management Holding S.A.0.96%
Blackstone Inc.0.92%
Vestal Point Capital, LP0.84%
HEIGHTS CAPITAL MANAGEMENT, INC0.83%
Hudson Bay Capital Management LP0.72%
Rossmore Private Capital0.70%
Pentwater Capital Management LP0.60%
SYQUANT CAPITAL SAS0.59%
Andera Partners0.51%

Funds

Fund% owned
BlackRock Health Sciences Opportunities Portfolio0.75%
BlackRock Health Sciences Term Trust0.11%
Fidelity Nasdaq Composite Index Fund0.07%
Dimensional VA International Small Portfolio0.00%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. NYXH. Cached 15 minutes.

Some panels did not load: insider.